NEW YORK (GenomeWeb) – Investment bank Piper Jaffray on Thursday initiated coverage of Veracyte with an overweight rating on the firm's stock and a $21 price target.
Registering provides access to this and other free content.
Already have an account?Login Now.
The White House seeks to update how biotechnology products are regulated.
Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.
In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.
The American Society of Human Genetics has issued a position statement on genetic testing of children.